Phase 4 Study of the Efficacy of Losartan Based Therapy in Hypertensives With and Without Diabetes

• Status: Withdrawn
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To study antihypertensive efficacy of 12 weeks of Losartan based therapy Resilo (Losartan) and Resilo-H (Losartan+ Hydrochlorothiazide) in uncontrolled hypertensive and diabetic hypertensive patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of The West Indies
• Collaborator: Caribbean College of Family Physicians
• Treatments: Amlodipine; Hydrochlorothiazide; Losartan

Criteria

Inclusion Criteria:

• Willing to sign Informed Consent Form.

• Patients of either sex above 18 years of age.

• Patients not previously diagnosed with hypertension and with sitting blood pressure > 140/90 mmHg on two readings 15 minutes apart.

• Newly diagnosed hypertensive patients.

• Hypertensive patients on other antihypertensive therapies but not at goal

• Diabetes defined as patient on insulin therapy or oral diabetic therapy or fasting blood glucose on screening > 7 mmol/L

Exclusion Criteria:

• Patients with history of allergic reaction to any angiotensin II antagonist or a thiazide diuretic

• Patients with history suggestive secondary hypertension

• Patients who have taken Resilo or Resilo-H or other losartan based treatment in past three months of study inclusion.

• Patients with chronic renal failure or who on screening has serum creatinine >150 µmol/L

• Patients who is participating concurrently in another clinical trial.